Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

ADAR antibody (AA 367-471) (HRP)

This anti-ADAR antibody is a Rabbit Polyclonal antibody detecting ADAR in ELISA. Suitable for Human.
Catalog No. ABIN7150636

Quick Overview for ADAR antibody (AA 367-471) (HRP) (ABIN7150636)

Target

See all ADAR Antibodies
ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Reactivity

  • 85
  • 29
  • 24
  • 2
  • 1
  • 1
  • 1
  • 1
Human

Host

  • 81
  • 5
  • 1
Rabbit

Clonality

  • 73
  • 14
Polyclonal

Conjugate

  • 38
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
This ADAR antibody is conjugated to HRP

Application

  • 58
  • 27
  • 27
  • 21
  • 21
  • 10
  • 10
  • 9
  • 8
  • 6
  • 3
  • 3
  • 1
ELISA
  • Binding Specificity

    • 15
    • 15
    • 6
    • 4
    • 4
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 367-471

    Cross-Reactivity

    Human

    Purification

    >95%, Protein G purified

    Immunogen

    Recombinant Human Double-stranded RNA-specific adenosine deaminase protein (367-471AA)

    Isotype

    IgG
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Preservative: 0.03 % Proclin 300
    Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

    Preservative

    ProClin

    Precaution of Use

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    -20 °C,-80 °C

    Storage Comment

    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Target

    ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

    Alternative Name

    ADAR

    Background

    Background: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, pre-mRNA splicing by altering splice site recognition sequences, RNA stability by changing sequences involved in nuclease recognition, genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5\'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.

    Aliases: 136 kDa double-stranded RNA-binding protein antibody, 136 kDa double stranded RNA binding protein antibody, Adar 1 antibody, ADAR antibody, Adar1 antibody, Adenosine deaminase acting on RNA 1 A antibody, Adenosine deaminase RNA specific 1 antibody, Adenosine deaminase RNA specific antibody, Adenosine deaminase that act on RNA antibody, AGS6 antibody, AV242451 antibody, Double stranded RNA specific adenosine deaminase antibody, Double-stranded RNA-specific adenosine deaminase antibody, Double-stranded RNA-specific editase Adar antibody, DRADA antibody, Dsh antibody, Dsrad antibody, DSRAD_HUMAN antibody, dsRNA adenosine deaminase antibody, EC 3.5.4.- antibody, G1P1 antibody, IFI 4 antibody, IFI-4 antibody, IFI4 antibody, Ifi4 protein antibody, Interferon induced protein 4 antibody, Interferon inducible protein 4 antibody, Interferon-inducible protein 4 antibody, K88DSRBP antibody, mZaADAR antibody, P136 antibody, Pre-mRNA adenosine deaminase antibody, RNA adenosine deaminase 1 antibody, RNA-editing deaminase 1 antibody, RNA-editing enzyme 1 antibody

    UniProt

    P55265

    Pathways

    Protein targeting to Nucleus
You are here:
Chat with us!